The relation between total joint arthroplasty and risk for serious cardiovascular events in patients with moderate-severe osteoarthritis: Propensity score matched landmark analysis

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Ravi, Bheeshma ^a,b,c   Croxford, Ruth ^d   Austin, Peter C ^b,d   Lipscombe, Lorraine ^a,b,c   Bierman, Arlene S ^a,b,d,e   Harvey, Paula J ^a,c   Hawker, Gillian A ^a,b,c,d,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART PROTECTION; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROPENSITY SCORE MATCHED LANDMARK ANALYSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ONTARIO; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PROPENSITY SCORE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84888153049     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6187     Document Type: Article

References (91)

1. Global atlas on cardiovascular disease prevention and control. Policies, strategies and interventions. World Health Organization, World Heart Federation, and World Stroke Organization, 2011.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855-64.
3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-53.
4. World Health Organization. The global burden of disease: 2004 update. WHO, 2008.
5. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;334:885-8.
6. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 1997;20:704-8.
7. Ho JE, Paultre F, Mosca L, Women's Pooling Project. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke 2003;34:2812-6.
8. McCarron P, Greenwood R, Elwood P, Shlomo YB, Bayer A, Baker I, et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke. Public Health 2001;115:12-20.
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
10. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-7.
11. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997;96:3243-7.
12. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
13. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.
14. Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation 1994;90:2225-9.
15. Bunker SJ, Colquhoun DM, Esler MD, Hickie IB, Hunt D, Jelinek VM, et al. "Stress" and coronary heart disease: psychosocial risk factors. Med J Austr 2003;178:272-6.
16. Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Waugh R, Georgiades A, et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA 2005;293:1626-34.
17. Bavry AA, Khaliq A, Gong Y, Handberg EM, Cooper-Dehoff RM, Pepine CJ. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med 2011;124:614-20.
18. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006;296:1653-6.
19. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
20. Kritharides L. Inflammatory markers and outcomes in cardiovascular disease. PLoS Med 2009;6:e1000147.
21. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 200216;106:388-91.
22. Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. [Erratum appears in Circulation 2005;111:1717]. Circulation 2005;111:369-76.
23. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012;380:219-29.
24. Agency for Healthcare Research and Quality. Physical activity and older Americans: benefits and strategies. www.ahrqgov/ppip/activityhtm. June 2002.
25. Roger VL GA, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125:e2-220.
26. Adamson J, Lawlor DA, Ebrahim S. Chronic diseases, locomotor activity limitation and social participation in older women: cross sectional survey of British Women's Heart and Health Study. Age Ageing 2004;33:293-8.
27. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60:91-7.
28. Hawker GA Badley EM, Jaglal S, Dunn S, Croxford R, Ko B, et al. Musculoskeletal conditions. In: Bierman AS, ed. Project for an Ontario Women's Health Evidence-Based Report: vol 2: Toronto. 2010.
29. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011;342:d1165.
30. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6.
31. Davis MC, Zautra AJ, Reich JW. Vulnerability to stress among women in chronic pain from fibromyalgia and osteoarthritis. Ann Behav Med 2001;23:215-26.
32. Weinberger M, Tierney WM, Booher P, Hiner SL. Social support, stress and functional status in patients with osteoarthritis. Soc Sci Med 1990;30:503-8.
33. Creamer P, Lethbridge-Cejku M, Costa P, Tobin JD, Herbst JH, Hochberg MC. The relationship of anxiety and depression with self-reported knee pain in the community: data from the Baltimore Longitudinal Study of Aging. Arthritis Care Res 1999;12:3-7.
34. Zautra AJ, Smith BW. Depression and reactivity to stress in older women with rheumatoid arthritis and osteoarthritis. Psychosom Med 2001;63:687-96.
35. Memel DS, Kirwan JR, Sharp DJ, Hehir M. General practitioners miss disability and anxiety as well as depression in their patients with osteoarthritis. Br J Gen Pract 2000;50:645-8.
36. Scopaz KA, Piva SR, Wisniewski S, Fitzgerald GK. Relationships of fear, anxiety, and depression with physical function in patients with knee osteoarthritis. Arch Phys Med Rehabil 2009;90:1866-73.
37. Lamb SE, Frost H. Recovery of mobility after knee arthroplasty: expected rates and influencing factors. J Arthroplasty 2003;18:575-82.
38. Sicard-Rosenbaum L, Light KE, Behrman AL. Gait, lower extremity strength, and self-assessed mobility after hip arthroplasty. J Gerontol A Biol Sci Med Sci 2002;57:M47-51.
39. Hawker GA, Wright JG, Coyte PC, Williams JI, Harvey B, Glazier R, et al. Differences between men and women in the rate of use of hip and knee arthroplasty. N Engl J Med 2000;342:1016-22.
40. Hawker GA, Guan J, Croxford R, Coyte PC, Glazier RH, Harvey BJ, et al. A prospective population-based study of the predictors of undergoing total joint arthroplasty. Arthritis Rheum 2006;54:3212-20.
41. Hawker GA, Wright JG, Badley EM, Coyte PC. Perceptions of, and willingness to consider, total joint arthroplasty in a population-based cohort of individuals with disabling hip and knee arthritis. Arthritis Rheum 2004;51:635-41.
42. Hawker GA, Wright JG, Coyte PC, Williams JI, Harvey B, Glazier R, et al. Determining the need for hip and knee arthroplasty: the role of clinical severity and patients' preferences. Med Care 2001;39:206-16.
43. Canadian Institute for Health Information. The international statistical classification of diseases and related health problems, 10th revision. Canadian Institute for Health Information, 2003.
44. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363-71.
45. Beyersmann J, Gastmeier P, Wolkewitz M, Schumacher M. An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol 2008;61:1216-21.
46. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008;26:3913-5.
47. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
48. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-70.
49. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007;369:750-6.
50. Tu K, Chen Z, Lipscombe LL, Canadian Hypertension Education Program Outcomes Research T. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ 2008;178:1429-35.
51. Friedman B, Heisel M, Delavan R. Validity of the SF-36 five-item Mental Health Index for major depression in functionally impaired, community-dwelling elderly patients. J Am Geriatr Soc 2005;53:1978-85.
52. Austin P. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.
53. Austin P. A Tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res 2011;46:119-51.
54. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-61.
55. Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med 2011;30:1292-301.
56. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107.
57. Austin PC. Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analyses. Int J Biostat 2009;5:Article 13.
58. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994;50:1064-72.
59. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303.
60. Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster J-Y. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg 2004;86-A:963-74.
61. Jandric S, Manojlovic S. Quality of life of men and women with osteoarthritis of the hip and arthroplasty: assessment by WOMAC questionnaire. Am J Phys Med Rehabil 2009;88:328-35.
62. Jones CA, Beaupre LA, Johnston DWC, Suarez-Almazor ME. Total joint arthroplasties: current concepts of patient outcomes after surgery. Rheum Dis Clin North Am 2007;33:71-86.
63. Jones CA, Voaklander DC, Johnston DW, Suarez-Almazor ME. Health related quality of life outcomes after total hip and knee arthroplasties in a community based population. J Rheumatol 2000;27:1745-52.
64. Mariconda M, Galasso O, Costa GG, Recano P, Cerbasi S. Quality of life and functionality after total hip arthroplasty: a long-term follow-up study. BMC Musculoskelet Disord 2011;12:222.
65. Montin L, Leino-Kilpi H, Suominen T, Lepisto J. A systematic review of empirical studies between 1966 and 2005 of patient outcomes of total hip arthroplasty and related factors. J Clin Nurs 2008;17:40-5.
66. Quintana JM, Escobar A, Arostegui I, Bilbao A, Azkarate J, Goenaga JI, et al. Health-related quality of life and appropriateness of knee or hip joint replacement. Arch Intern Med 2006;166:220-6.
67. Bauman S, Williams D, Petruccelli D, Elliott W, de Beer J. Physical activity after total joint replacement: a cross-sectional survey. Clin J Sport Med 2007;17:104-8.
68. Mahon JL, Bourne RB, Rorabeck CH, Feeny DH, Stitt L, Webster-Bogaert S. Health-related quality of life and mobility of patients awaiting elective total hip arthroplasty: a prospective study. CMAJ 2002;167:1115-21.
69. Stevens M, Reininga IHF, Bulstra SK, Wagenmakers R, van den Akker-Scheek I. Physical activity participation among patients after total hip and knee arthroplasty. Clin Geriatr Med 2012;28:509-20.
70. Woolf VJ, Charnley GJ, Goddard NJ. Weight changes after total hip arthroplasty. J Arthroplasty 1994;9:389-91.
71. Haapanen N, Miilunpalo S, Vuori I, Oja P, Pasanen M. Association of leisure time physical activity with the risk of coronary heart disease, hypertension and diabetes in middle-aged men and women. Int J Epidemiol 1997;26:739-47.
72. Nelson L, Jennings GL, Esler MD, Korner PI. Effect of changing levels of physical activity on blood-pressure and haemodynamics in essential hypertension. Lancet 1986;2:473-6.
73. Pereira MA, Folsom AR, McGovern PG, Carpenter M, Arnett DK, Liao D, et al. Physical activity and incident hypertension in black and white adults: the Atherosclerosis Risk in Communities Study. Prevent Med 1999;28:304-12.
74. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006;26:968-76.
75. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-28.
76. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-16.
77. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991;325:147-52.
78. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.
79. Prior JA RC, Jordan KP, Kadam UT. Comorbidity Cohort (2C) study: cardiovascular disease severity and comorbid osteoarthritis in primary care. BMC Health Serv Res 2012;12:295.
80. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care 2002;8(15 Suppl):S383-91.
81. Vogeli C, Shields AE, Lee TA, Gibson TB, Marder WD, Weiss KB, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med 2007;22(Suppl 3):391-5.
82. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
83. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-84.
84. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
85. White WB. Cardiovascular risk, hypertension, and NSAIDs. Curr Pain Headache Rep 2007;11:428-35.
86. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999;99:1165-72.
87. Engstrom G, Gerhardsson de Verdier M, Rollof J, Nilsson PM, Lohmander LS. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthritis Cartilage 2009;17:168-73.
88. Han C, Yang I, Lee W, Park Y, Park K. Correlation between metabolic syndrome and knee osteoarthritis: data from the Korean National Health and Nutrition Examination Survey (KNHANES). BMC Public Health 2013;13:603.
89. Inoue R, Ishibashi Y, Tsuda E, Yamamoto Y, Matsuzaka M, Takahashi I, et al. Medical problems and risk factors of metabolic syndrome among radiographic knee osteoarthritis patients in the Japanese general population. J Orthop Sci 2011;16:704-9.
90. Udell JA, Steg PG, Scirica BM, Smith SC Jr, Ohman EM, Eagle KA, et al. Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis. Arch Intern Med 2012;172:1086-95.
91. Quintana JM, Arostegui I, Escobar A, Azkarate J, Goenaga JI, Lafuente I. Prevalence of knee and hip osteoarthritis and the appropriateness of joint replacement in an older population. Arch Intern Med 2008;168:1576-84.